A Phase 2b Open-Label, Single Arm Study to Evaluate the Efficacy of Voxelotor for Improving Oxygen Saturation and Reducing Ventilatory Support Requirements in Adult Patients With New or Increased Oxygen Requirement
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Voxelotor (Primary)
- Indications Hypoxaemia
- Focus Therapeutic Use
Most Recent Events
- 14 Apr 2024 Status changed from suspended to discontinued.
- 06 Oct 2023 Status changed from recruiting to suspended. (Pending Protocol amendment, enrollment is on hold. There are no active subjects currently.)
- 13 Jul 2023 Planned End Date changed from 1 May 2023 to 1 Jun 2024.